{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:57:44Z","timestamp":1761533864436,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":4052,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1111\/j.1538-7836.2011.04510.x","type":"journal-article","created":{"date-parts":[[2011,9,19]],"date-time":"2011-09-19T15:04:16Z","timestamp":1316444656000},"page":"2328-2329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Factor VIII inhibitors in previously treated hemophilic patients"],"prefix":"10.1016","volume":"9","author":[{"given":"P.M.","family":"MANNUCCI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2011.04510.x_bb0010","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1111\/j.1538-7836.2011.04496.x","article-title":"Best evidence on B\u2010domain deletion and the immunogenicity of recombinant factor VIII","volume":"9","author":"Aledort","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04510.x_bb0015","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1111\/j.1538-7836.2011.04480.x","article-title":"Concentrate related inhibitor risk: is a difference always real?","volume":"9","author":"Iorio","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04510.x_bb0020","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1111\/j.1538-7836.2006.02233.x","article-title":"Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates","volume":"4","author":"Kempton","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04510.x_bb0025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2516.2007.01634.x","article-title":"A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose","volume":"14","author":"Rubinger","year":"2008","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2011.04510.x_bb0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2516.2010.02235.x","article-title":"Inhibitors in previously treated patients: a review of the literature","volume":"16","author":"Kempton","year":"2010","journal-title":"Haemophilia"},{"issue":"Suppl. 5","key":"10.1111\/j.1538-7836.2011.04510.x_bb0035","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2516.2007.01580.x","article-title":"Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma\u2010product exposed toddlers)","volume":"13","author":"Mannucci","year":"2007","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2011.04510.x_bb0040","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1538-7836.2010.03823.x","article-title":"Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma\u2010derived or recombinant factor VIII concentrates: a systematic review","volume":"8","author":"Iorio","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04510.x_bb0045","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJM198008213030803","article-title":"Efficacy of prothrombin\u2010complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial","volume":"303","author":"Lusher","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04510.x_bb0050","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJM198109243051301","article-title":"The effect of activated prothrombin\u2010complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double\u2010blind clinical trial","volume":"305","author":"Sjamsoedin","year":"1981","journal-title":"N Engl J Med"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2011.04510.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362207458X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362207458X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2011.04510.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:53:22Z","timestamp":1761533602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362207458X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":9,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S153878362207458X"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04510.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"type":"print","value":"1538-7836"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factor VIII inhibitors in previously treated hemophilic patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04510.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}